Skip to content

Randomized controlled clinical trial on the timing of CRRT in patients with brain injury complicated with acute moderate and severe hypernatremia.

Randomized controlled clinical trial on the timing of CRRT in patients with brain injury complicated with acute moderate and severe hypernatremia.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082349
Enrollment
Unknown
Registered
2024-03-27
Start date
2024-03-30
Completion date
Unknown
Last updated
2024-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain injury complicated with hypernatremia

Interventions

Early treatment group:The early treatment group started CRRT treatment immediately after randomization.
Standard treatment group:After randomization, CRRT indications appear or blood sodium exceeds 170mmol/L, and CRRT treatment is started.

Sponsors

The First Affiliated Hospital of the Air Force Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age =18 years old; 2. Diagnosis of brain injury, including: ? acute intracranial hemorrhage (such as intracerebral hemorrhage, subdural hematoma, epidural hematoma, etc.); ? Ischemic stroke (cerebral infarction); ? Mild to moderate traumatic brain injury (open or closed); ? Determine the types of brain tumors (such as gliomas and meningiomas); 3. Acute moderate and severe hypernatremia; 4. Patient/legal representative/legal supervisor Guardian/family members sign informed consent form.

Exclusion criteria

Exclusion criteria: 1. Low volume hypernatremia; 2. Pregnancy or breast-feeding period; 3. Previous chronic kidney disease (EGFR < 30 ml/min); Patients who have participated in clinical trials of other drugs/devices within 4.3 months; 5. The estimated survival time is less than 72 hours, or the clinical condition is not expected to be stable within 72 hours; 6. Severe heart, liver, lung or other important organ dysfunction, which may affect the test results or patient safety; 7. Any other illness or condition that the researcher thinks is not suitable to participate in this study.

Design outcomes

Primary

MeasureTime frame
28-day survival rate;

Secondary

MeasureTime frame
Nerve function recovery;High sodium Correction of anemia;24h osmotic demyelination;

Countries

China

Contacts

Public ContactMing Bai

The First Affiliated Hospital of the Air Force Medical University

mingbai1983@126.com+86 137 7210 4001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026